This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate.